CCRCC

(redirected from Clear Cell Renal Cell Carcinoma)
AcronymDefinition
CCRCCClear Cell Renal Cell Carcinoma
CCRCCCanada-Czech Republic Chamber of Commerce (est. 1994)
CCRCCCentral Connecticut Radio Control Club (Farmington, CT)
CCRCCCedar City Radio Control Club (Utah)
CCRCCCircle C Ranch Cycling Club (Austin, TX)
CCRCCChampaign County Radio Control Club (Champaign, IL)
CCRCCCatholic Charismatic Renewal for the City of Chicago
References in periodicals archive ?
Cambridge, Massachusetts-based drug developer X4 Pharmaceuticals has released updated results from Phase 1 of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta (axitinib) in patients with clear cell renal cell carcinoma (ccRCC), the company said.
Loss of chromosome analysis at 3p in clear cell renal cell carcinoma with or without elevated pretreatment C-reactive protein
Clear cell renal cell carcinoma with borderline features of clear cell papillary renal cell carcinoma: combined morphologic, immunohistochemical, and cytogenetic analysis.
Therefore, the diagnosis of rhabdoid variant of clear cell renal cell carcinoma was made.
All the radical nephrectomy specimens diagnosed as renal cell carcinoma included clear cell renal cell carcinoma 21 (70%) cases clear cell papillary renal cell carcinoma 03 (10%) papillary renal cell carcinoma 02 (6.
Solitary and multiple isolated metastasis of clear cell renal cell carcinoma to the pancreas: an indication for pancreatic surgery.
TKI treatment represents an effective treatment option for patients with metastatic clear cell renal cell carcinoma, allowing an average progression-free survival of 11 months.
RCC, which develops in the lining of tubules (very narrow tubes) in the kidneys, accounts for nine out of 10 cases of renal cancer, and a specific subtype called clear cell renal cell carcinoma (ccRCC) occurs most often.
X4P-001-IO, an oral small molecule inhibitor of C-X-C receptor type 4 (CXCR4), the receptor for the chemokine CXCL12, is currently in Phase 1/2 testing in refractory clear cell renal cell carcinoma (ccRCC) and other solid tumor indications.
have entered a clinical collaboration to evaluate BMS' Opdivo in combination with Calithera's CB-839 in patients with clear cell renal cell carcinoma (ccRCC).
Full browser ?